688712 北芯生命
交易中 05-06 13:49:02
资讯
新帖
简况
北芯生命(688712)3月31日股东户数1.92万户,较上期减少42.98%
证券之星 · 04-25
北芯生命(688712)3月31日股东户数1.92万户,较上期减少42.98%
北芯生命:第一季度净利润同比增长121.83%
证券之星 · 04-24
北芯生命:第一季度净利润同比增长121.83%
每周股票复盘:北芯生命(688712)部分募投项目增加实施地点
证券之星 · 03-15
每周股票复盘:北芯生命(688712)部分募投项目增加实施地点
北芯生命:MEMS传感器技术目前主要应用于FFR相关产品并聚焦冠脉领域
证券日报 · 03-13
北芯生命:MEMS传感器技术目前主要应用于FFR相关产品并聚焦冠脉领域
北芯生命(688712)披露部分募投项目增加实施地点公告,3月9日股价下跌2.68%
证券之星 · 03-09
北芯生命(688712)披露部分募投项目增加实施地点公告,3月9日股价下跌2.68%
北芯生命:公司核心产品IVUS系统于2024年在欧洲获批上市
证券日报 · 03-02
北芯生命:公司核心产品IVUS系统于2024年在欧洲获批上市
每周股票复盘:北芯生命(688712)2025年净利增284.93%
证券之星 · 03-01
每周股票复盘:北芯生命(688712)2025年净利增284.93%
北芯生命发布2025年度业绩快报,盈利0.806亿元
证券之星 · 02-27
北芯生命发布2025年度业绩快报,盈利0.806亿元
北芯生命正式登陆科创板 心血管精准诊疗格局加速重构
21世纪经济报道 · 02-06
北芯生命正式登陆科创板 心血管精准诊疗格局加速重构
北芯生命(688712.SH)股票将于2月5日在上科创板上市
智通财经 · 02-03
北芯生命(688712.SH)股票将于2月5日在上科创板上市
北芯生命(688712.SH):网上发行最终中签率为0.0326%
中金财经 · 01-26
北芯生命(688712.SH):网上发行最终中签率为0.0326%
A股申购 | 北芯生命(688712.SH)开启申购 专注于心血管疾病诊疗领域
智通财经 · 01-26
A股申购 | 北芯生命(688712.SH)开启申购 专注于心血管疾病诊疗领域
【新股】一图读懂北芯生命
中金财经 · 01-23
【新股】一图读懂北芯生命
公司概况
公司名称:
深圳北芯生命科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2026-02-05
主营业务:
深圳北芯生命科技股份有限公司的主营业务是心血管疾病精准诊疗创新医疗器械研发、生产和销售。公司的主要产品是冠脉血管介入产品、外周血管介入产品、电生理产品。公司获财政部、工业和信息化部评定的新一轮第二批重点“小巨人”企业荣誉称号,并再次入选深圳市工业和信息化局颁发的市制造业单项冠军企业名单。
发行价格:
17.52
{"stockData":{"symbol":"688712","market":"SH","secType":"STK","nameCN":"北芯生命","latestPrice":43.16,"timestamp":1778046542000,"preClose":41.69,"halted":0,"volume":4036139,"delay":0,"changeRate":0.0353,"floatShares":37114700,"shares":417000000,"eps":0.2521,"marketStatus":"交易中","change":1.47,"latestTime":"05-06 13:49:02","open":41.95,"high":43.63,"low":41.78,"amount":174000000,"amplitude":0.0444,"askPrice":43.17,"askSize":10,"bidPrice":43.16,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.2521,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778050800000},"marketStatusCode":2,"adr":0,"adjPreClose":41.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778031000000,1778038200000],[1778043600000,1778050800000]],"highLimit":45.86,"lowLimit":37.52,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":417000000,"isCdr":false,"pbRate":9.85,"roa":"--","peRate":171.201904,"roe":"3.13%","epsLYR":0.22,"committee":-0.692525,"marketValue":17998000000,"turnoverRate":0.1087,"status":0,"floatMarketCap":1602000000},"requestUrl":"/m/hq/s/688712/wiki","defaultTab":"wiki","newsList":[{"id":"2630870539","title":"北芯生命(688712)3月31日股东户数1.92万户,较上期减少42.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870539","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870539?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:07","pubTimestamp":1777108059,"startTime":"0","endTime":"0","summary":"证券之星消息,近日北芯生命披露,截至2026年3月31日公司股东户数为1.92万户,较2月5日减少1.45万户,减幅为42.98%。户均持股数量由上期的1.24万股增加至2.17万股,户均持股市值为82.52万元。在医疗器械行业个股中,北芯生命股东户数低于行业平均水平,截至3月31日,医疗器械行业平均股东户数为2.19万户。从股价来看,2026年2月5日至2026年3月31日,北芯生命区间跌幅为23.43%,在此期间股东户数减少1.45万户,减幅为42.98%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688712","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629849708","title":"北芯生命:第一季度净利润同比增长121.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629849708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629849708?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:30","pubTimestamp":1777033830,"startTime":"0","endTime":"0","summary":"北芯生命(688712.SH)公告称,2026年第一季度实现营业收入1.85亿元,同比增长45.36%;归属于上市公司股东的净利润为4571.09万元,同比增长121.83%。业绩变动主要系公司精准PCI产品销售规模持续增长、公司管线日益丰富、产品组合协同增效、深化渠道联动等,也进一步释放新的增长动力;以及公司销售规模增长,前期在营销网络搭建、产能建设等方面的投入逐步释放效能,带来的大幅上涨。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400061968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619120668","title":"每周股票复盘:北芯生命(688712)部分募投项目增加实施地点","url":"https://stock-news.laohu8.com/highlight/detail?id=2619120668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619120668?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:02","pubTimestamp":1773511339,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,北芯生命报收于40.16元,较上周的39.87元上涨0.73%。本周,北芯生命3月12日盘中最高价报41.74元。本周关注点公司公告汇总:北芯生命拟增加坪山生物医药产业加速器园区为募投项目新实施地点。深圳北芯生命科技股份有限公司于2026年3月6日召开第二届董事会第十一次会议,审议通过《关于使用自有资金支付募投项目所需部分资金并以募集资金等额置换的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619914081","title":"北芯生命:MEMS传感器技术目前主要应用于FFR相关产品并聚焦冠脉领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2619914081","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619914081?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:12","pubTimestamp":1773400320,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月13日,北芯生命在互动平台回答投资者提问时表示,MEMS传感器技术是公司核心技术之一,目前主要应用于FFR相关产品并聚焦冠脉领域。关于具体产品规划及进展情况,请以公司后续披露的定期报告及相关公告为准。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxre4051236.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxre4051236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688712","BK0251","MEMS","FFR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618624054","title":"北芯生命(688712)披露部分募投项目增加实施地点公告,3月9日股价下跌2.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618624054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618624054?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:16","pubTimestamp":1773065784,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘,北芯生命报收于38.8元,较前一交易日下跌2.68%,最新总市值为161.8亿元。近日,深圳北芯生命科技股份有限公司发布《关于部分募投项目增加实施地点的公告》。公告显示,公司拟增加“广东省深圳市坪山区坑梓街道金沙社区临惠6号坪山生物医药产业加速器园区”为募投项目“介入类医疗器械产业化基地建设项目”的实施地点。本次仅增加实施地点,不涉及募集资金用途及实施主体变更,不会对募投项目实施造成实质性影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616584333","title":"北芯生命:公司核心产品IVUS系统于2024年在欧洲获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2616584333","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616584333?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:38","pubTimestamp":1772458680,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月2日,北芯生命在互动平台回答投资者提问时表示,公司核心产品IVUS系统于2024年在欧洲获批上市,为首个在海外获批上市(欧盟MDR)的国产IVUS产品;核心产品FFR系统于2020年在欧洲获批上市,为首个在海外获批上市(欧盟MDR)的国产FFR产品,产品凭借有显著临床价值的差异化创新,在满足过往未被完全满足的重要临床需求方面,持续获得国内外专家的广泛认可,产品已进入全球超过60个国家和地区,在超过2000家医院实现临床应用。产品暂未进入美国市场。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-02/doc-inhprfsc4458451.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-02/doc-inhprfsc4458451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616431398","title":"每周股票复盘:北芯生命(688712)2025年净利增284.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616431398","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616431398?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:05","pubTimestamp":1772301916,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,北芯生命报收于41.18元,较上周的39.48元上涨4.31%。本周,北芯生命2月27日盘中最高价报41.8元。本周关注点业绩披露要点:北芯生命2025年归母净利润8,062.19万元,同比增长284.93%。公司公告汇总:北芯生命2025年海外市场收入同比增长超130%。公司公告汇总深圳北芯生命科技股份有限公司发布2025年度业绩快报,营业总收入54,210.81万元,同比增长71.23%;营业利润8,906.80万元,实现扭亏为盈。归属于母公司所有者的净利润8,062.19万元,上年同期为亏损4,359.62万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614588073","title":"北芯生命发布2025年度业绩快报,盈利0.806亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614588073","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614588073?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:31","pubTimestamp":1772181089,"startTime":"0","endTime":"0","summary":"证券之星消息,北芯生命近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润盈利0.806亿元,同比增长284.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700026564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609533633","title":"北芯生命正式登陆科创板 心血管精准诊疗格局加速重构","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533633","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609533633?lang=zh_cn&edition=full","pubTime":"2026-02-06 07:00","pubTimestamp":1770332400,"startTime":"0","endTime":"0","summary":"科创板“第五套标准”重启后首家成功上市的创新医疗器械企业正式诞生。 2月5日,深圳北芯生命科技股份有限公司正式在上海证券交易所科创板上市,发行价格为17.52元/股,发行5700万股,公开发行股票的比例占本次发行后公司总股本的13.67%。 同花顺数据显示,北芯生命当天以50.31元/股高开,盘内涨幅一度超210%。但毋庸置疑,北芯生命的成功上市,将加快重塑心血管疾病精准诊疗创新医疗器械的研发格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-06/doc-inhkvret2324506.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-06/doc-inhkvret2324506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608873052","title":"北芯生命(688712.SH)股票将于2月5日在上科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2608873052","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608873052?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:09","pubTimestamp":1770120576,"startTime":"0","endTime":"0","summary":"智通财经APP讯,北芯生命(688712.SH)发布公告,公司股票将于2026年2月5日在上海证券交易所科创板上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北芯生命(688712.SH)股票将于2月5日在上科创板上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606183248","title":"北芯生命(688712.SH):网上发行最终中签率为0.0326%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606183248","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606183248?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:57","pubTimestamp":1769432226,"startTime":"0","endTime":"0","summary":"回拨机制启动后,网下最终发行数量为3,192.0000万股,占扣除最终战略配售数量后发行数量的70.00%;网上最终发行数量为1,368.0000万股,占扣除最终战略配售数量后发行数量的30.00%。回拨机制启动后,网上发行最终中签率为0.03264275%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260126/31973172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688712"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606269584","title":"A股申购 | 北芯生命(688712.SH)开启申购 专注于心血管疾病诊疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2606269584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606269584?lang=zh_cn&edition=full","pubTime":"2026-01-26 06:29","pubTimestamp":1769380189,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,1月26日,北芯生命开启申购,发行价格为17.52元/股,申购上限为0.9万股,行业市盈率41.36倍,属于上交所,中金公司为其保荐机构。招股书显示,北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的技术企业,亦致力于开发为心血管疾病诊疗带来变革的精准解决方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688712","159982","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605742546","title":"【新股】一图读懂北芯生命","url":"https://stock-news.laohu8.com/highlight/detail?id=2605742546","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605742546?lang=zh_cn&edition=full","pubTime":"2026-01-23 13:14","pubTimestamp":1769145248,"startTime":"0","endTime":"0","summary":"证券之星消息,北芯生命1月26日网上申购,申购代码为787712,中签号公布日期为1月28日。该股概况请见下图: 为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/23/20260123504386.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/23/20260123504386.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260123/31966886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688712"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778046581401,"stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":0.0968},{"period":"3month","weight":1.3796},{"period":"ytd","weight":1.3796}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳北芯生命科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"19207人(较上一季度减少42.98%)","perCapita":"1932股","listingDate":"2026-02-05","address":"广东省深圳市龙华区民治街道北站社区鸿荣源北站中心A塔2102","registeredCapital":"41700万元","survey":" 深圳北芯生命科技股份有限公司的主营业务是心血管疾病精准诊疗创新医疗器械研发、生产和销售。公司的主要产品是冠脉血管介入产品、外周血管介入产品、电生理产品。公司获财政部、工业和信息化部评定的新一轮第二批重点“小巨人”企业荣誉称号,并再次入选深圳市工业和信息化局颁发的市制造业单项冠军企业名单。","listedPrice":17.52},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北芯生命(688712)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北芯生命(688712)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北芯生命,688712,北芯生命股票,北芯生命股票老虎,北芯生命股票老虎国际,北芯生命行情,北芯生命股票行情,北芯生命股价,北芯生命股市,北芯生命股票价格,北芯生命股票交易,北芯生命股票购买,北芯生命股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北芯生命(688712)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北芯生命(688712)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}